Blue Jay Capital Management’s ResMed RMD Stock Holding History

Blue Jay Capital Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-145,000	Closed	-$9M	–	25
2016 Q4	$9M	Buy	+145,000	New	+$8.88M	5.43%	15

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $355M AUM

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Blue Jay Capital Management's RMD Position: Q1 2017 in Review

Blue Jay Capital Management sold out of ResMed (RMD) in Q1 2017, closing a stake of 145,000 shares — an estimated $9M sold.

Blue Jay Capital Management first reported a position in RMD in Q4 2016 and held it in 1 quarter. The position peaked at $9M in Q4 2016. 375 funds tracked by Wall St. Rank hold RMD as of Q1 2017.

Blue Jay Capital Management reported no remaining ResMed position as of Q1 2017 after selling out during the quarter.
Blue Jay Capital Management sold 145,000 ResMed shares in Q1 2017, an estimated $9M.
Blue Jay Capital Management first reported a position in ResMed in Q4 2016 and held it in 1 quarter.
Blue Jay Capital Management's ResMed position peaked at $9M in Q4 2016.
375 funds tracked by Wall St. Rank held ResMed as of Q1 2017.

Based on Blue Jay Capital Management's 13F filing for Q1 2017, filed 12 May 2017.